Jayasheel B G explains why India’s regulatory environment supports the country as a favoured clinical trials destination and examines the associated advantages and challenges faced by sponsors in this market.
India is making a name for itself in the international pharmaceutical arena as a preferred destination for leading global companies to conduct clinical trials and it is a challenge for both the government and the private sector to create a balance between ethics and trade...
Please login to read the full article.
